The Future of Type 1 Diabetes Management

Robert Busch, MD, and Robin S. Goland, MD, review the prevalence and pathophysiology of type 1 diabetes.

Dr Kimberly Simmons and Dr Teresa Quattrin examine the diagnostic process and importance of screening for type 1 diabetes.

Kimberly Simmons, MD, MPH/MSPH, reviews ADA guidelines recommendations for the management of type 1 diabetes.

Teresa Quattrin, MD, leads a discussion on the benefits of using medications for type 2 diabetes to manage patients who have type 1 diabetes.

Dr Teresa Quattrin discusses the significance of delaying the onset of type 1 diabetes.

Robin S. Goland, MD, and Kimberly Simmons, MD, MPH/MSPH, provide insight on teplizumab, which was recently approved by the FDA, to delay the progression of type 1 diabetes, and they discuss the implications of autoantibody detection in patients.

Dr Kimberly Simmons reviews key findings from an initial study and extended follow-up on the safety and efficacy of teplizumab in delaying the progression of type 1 diabetes.

Experts in endocrinology share their approach to patient selection for teplizumab in type 1 diabetes and the impact of a 2-year delay in the onset of the disease.

Kimberly Simmons, MD, MPH/MSPH, leads a discussion on long-term monitoring for patients with type 1 diabetes and which providers are most likely to administer and manage teplizumab treatment.

Teresa Quattrin, MD, reviews emerging clinical trial data on novel therapies to delay the progression of type 1 diabetes.

Experts in endocrinology share their approach to managing type 1 diabetes along with related health conditions.

Drs Robert Busch, Robin S. Goland, Kimberly Simmons, and Teresa Quattrin discuss strategies to facilitate screening of type 1 diabetes and improve management of disease.